Dendreon Corporation (Nasdaq: DNDN) is a biotechnology company developing targeted therapies for cancer. The Company’s lead investigational product candidate, Provenge®, is a cancer immunotherapy undergoing Phase III clinical trials for the potential treatment of advanced-stage prostate cancer. In addition to its therapeutic vaccines in clinical and preclinical development for a variety of cancers, Dendreon’s product pipeline also includes monoclonal antibodies and a pathway to small molecules. Dendreon has established important research and development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd.